healthcare
-
The real story behind the “October slide”
Changing seasons affect many people with Long COVID, myalgic encephalomyelitis, and other chronic illnesses, but not all in the same way. Research has a long way to go before it can explain the phenomenon.
-
Trans people with Long COVID navigate a new “dark age” in trans health
We spoke with and surveyed dozens of trans people navigating gender-affirming care and Long COVID during Trump’s second term.
-
I interviewed five people with Long COVID in prison. They are invisible in the system.
While there are no data sources on Long COVID in prison, experts suspect rates of the disease may be higher there than in the general population. They face high reinfection risks and poor access to medical care.
-
Research updates, August 18
Researchers found immune abnormalities in the intestines of people with Long COVID, according to a new preprint. The small study compared colon tissue samples and blood of 44 people with Long COVID to 13 controls who “recovered” from COVID-19, using several different analysis methods.
-
Breast cancer exposed the lack of care I receive for Long COVID
Cancer has a sadly well-worn path. It showed me that I deserve dignity and support for Long COVID.
-
How do you spot Long COVID misinformation?
In this episode, Miles Griffis and Betsy Ladyzhets talk to Long COVID physician, patient and advocate Zeest Khan about her Long COVID journey, how she looks at new research and off-label treatments as a physician, and how to spot misinformation and pseudoscience online.
-
Dysautonomia conference centers biomarkers and post-exertional malaise
The 14th annual Dysautonomia International conference outside Houston included presentations on the role of autoimmunity in dysautonomia and a biobank initiative for POTS research.
-
Experimental peptides are being advertised for Long COVID. But the evidence is trailing behind.
Some FDA-approved GLP-1s are being studied in clinical trials for the disease, but their results aren’t available yet. Experts caution against using experimental peptides for Long COVID.
-
Will the new COVID-19 antiviral be accessible?
In June, the Food and Drug Administration approved the drug Xocova (ensitrelvir) as the very first post-exposure prophylaxis for Sars-CoV-2, and if taken within 72 hours, it could stop a SARS-CoV-2 infection in its tracks. The drug is also being studied as a potential Long COVID treatment and even maybe as a preventative. But how…
-
FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible?
Shionogi, the Japanese company that makes Xocova (ensitrelvir), said the post-exposure prophylaxis drug will be available in mid-July in the U.S. and will have a list price of $1,400. But its impact will hinge on how easily people can access it, experts say.
Follow Us
get the latest long covid news
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance